2010 Annual Scientific Meeting and Exposition 2010 Annual ...

MAY 1PostersSaturday AfternoonPO-51: 3PO-52: 3PO-53: 3PO-54: 3PO-55: 3PO-56: 3Resistant Hypertension in Elderly Patients: Non-Dipper Pattern and ChronotherapyJose Enrique Lopez, 1 Alvaro Hermida, 1 Marta Pena, 1Luisa Romero, 1 Gaila Calvo, 1 Antonio Coca, 2 CarlosCalvo. 1 1 Hypertension and Vascular Unit, ComplejoHospitalario Universitario de Santiago, Santiago deCompostela, ES and 2 Hypertension Unit. HospitalClinico de Barcelona, ES.Olmesartan and Amlodipine Combination inAntihipertensive ChronotherapyJosé Enrique Lopez-Paz, 1 Alvaro Hermida, 1 MartaPena, 1 Luisa Romero, 1 Gaila Calvo, 1 Cristina Sierra, 2Antonio Coca, 2 Carlos Calvo. 1 1 Hypertensionand Vascular Risk Unit. Complejo HospitalarioUniversitario de Santiago, ES and 2 Hypertension Unit,Hospital Clinico de Barcelona, ES.Tolerability of Thiazides Compared to OtherAntihypertensive Drug ClassesHarikrishna J. Makani, 1 Sripal Bangalore, 2 SanthoshDevarapally, 1 Kuntal Pujara, 1 Jorge Silva Enciso, 1Franz H. Messerli. 1 1 St. Luke’s Roosevelt Hospitaland Columbia University College of Physicians andSurgeons, New York, NY, US and 2 Brigham andWomen’s Hospital, Harvard Medical School, Boston,MA, US.Long-Term Therapy with Aliskiren/Amlodipine/Hydrochlorothiazide Combination ProvidesEffective Blood Pressure Reduction with GoodTolerability in Patients with Moderate-To-SevereHypertensionAlexander Murray†, 1 Wolfgang Koenig, 2 Juan Garcia-Puig, 3 Samir Patel, 4 Molla Uddin, 4 Jack Zhang. 41 PharmQuest, US; 2 University of Ulm Medical Centre,DE; 3 Hospital Universitario La Paz, ES and 4 NovartisPharmaceuticals Corporation, US.Influence of Salt Intake on Target Organ Damages inTreated Hypertensive PatientsYuko Ohta, Takuya Tsuchihashi, Eri Hasegawa.National Kyushu Medical Center, Fukuoka, JP.Intensive Treatment with Combination Amlodipine/Valsartan Provides Greater AntihypertensiveEfficacy vs Moderate Treatment for HypertensivePatients Uncontrolled on ARB Monotherapy: TheExtra StudySuzanne Oparil†, 1 T. Giles, 2 E. Ofili, 3 B. Pitt, 4 Y. Seifu, 5R. Samuel, 5 R. Hilkert, 5 J. Sowers. 6 1 Univ. Alabamaat Birmingham, US; 2 Tulane Univ., US; 3 MorehouseSoM, US; 4 Univ. Michigan SoM, US; 5 Novartis, US and6 Univ. Missouri SoM, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track112